VEGFA and cancer: Indeed, the monoclonal anti-VEGF antibody bevacizumab [42,43] and the second-generation multitargeted receptor tyrosine kinase inhibitors (RTKIs) sunitinib [23,44] and sorafenib [3,45] have prolonged the life of numerous cancer patients.